Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHFUJT)

Drug Name

AZ-01, PEGylated interferon-beta Drug Info

Synonyms

PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne; AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis); AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMHFUJT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interferon-beta (IFNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PEGylated IFN beta 1-a	DMRH0D5	Type-2 diabetes	5A11	Approved	[3]
PLEGRIDY	DMAKXW9	Multiple sclerosis	8A40	Approved	[4]
Interferon beta-1a	DM1A6RV	Multiple sclerosis	8A40	Approved	[5]
FP-1201	DM823WQ	Acute lung injury	NB32.3	Phase 3	[6]
NU-100	DMA16IL	Multiple sclerosis	8A40	Phase 3	[2]
Biferonex	DM57B9J	Multiple sclerosis	8A40	Phase 3	[7]
PF-06823859	DM8C1H4	Dermatomycosis	EA60	Phase 2	[8]
Interferon beta 1a	DMQSA7H	Discovery agent	N.A.	Phase 2	[9]
ARX-424	DM4CZ2Y	Multiple sclerosis	8A40	Phase 1	[2]
Gene therapy, IFN-b	DMJP83V	Glioblastoma multiforme	2A00.0	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-beta (IFNB1)	TT4TZ8J	IFNB_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Allozyne Inc.
2	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
3	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
4	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
7	Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10	Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65.